Use of biologics for psoriasis in Central and Eastern European countries-Reference-Cited by-同舟云学术

Use of biologics for psoriasis in Central and Eastern European countries

Published:2015-09-14 Issue:11 Volume:29 Page:2222-2230
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Rencz F.¹²,Kemény L.³,Gajdácsi J.Z.⁴,Owczarek W.⁵,Arenberger P.⁶,Tiplica G.S.⁷,Stanimirović A.⁸,Niewada M.⁹,Petrova G.¹⁰,Marinov L.T.¹⁰,Péntek M.¹,Brodszky V.¹,Gulácsi L.¹

Affiliation:

1. Department of Health Economics; Corvinus University of Budapest; Budapest Hungary

2. Semmelweis University Doctoral School of Clinical Medicine; Budapest Hungary

3. Department of Dermatology and Allergology; University of Szeged; Szeged Hungary

4. National Health Insurance Fund Administration of Hungary; Budapest Hungary

5. Department of Dermatology; Military Institute of Medicine; Warsaw Poland

6. Department of Dermatology; Charles University 3rd Medical Faculty; Prague Czech Republic

7. Dermatology Clinic 2; Colentina Clinical Hospital; Carol Davila University of Medicine and Pharmacy; Bucharest Romania

8. Department of Clinical Medicine; University of Applied Health Sciences; Zagreb Croatia

9. Department of Experimental and Clinical Pharmacology; Medical University of Warsaw; Warsaw Poland

10. Department of Social Pharmacy and Pharmacoeconomics; Faculty of Pharmacy; Medical University; Sofia Bulgaria

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.13222/fullpdf

Reference39 articles.

1. European S3-guidelines on the systemic treatment of psoriasis vulgaris;Pathirana;J Eur Acad Dermatol Venereol,2009

2. European Medicines Agency http://www.ema.europa.eu/ema/

3. Quality of life in patients with psoriasis: a systematic literature review;Korte;J Investig Dermatol Symp Proc,2004

4. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary;Heredi;Eur J Health Econ,2014

5. Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity;Rencz;J Eur Acad Dermatol Venereol,2015

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health-Related Quality of Life in Psoriasis: Literature Review;Journal of Clinical Medicine;2024-08-07

2. Barriers and suggestions for improving the implementation of guidelines in the systemic treatment of moderate to severe psoriasis: A literature review;Annales de Dermatologie et de Vénéréologie;2024-06

3. Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries;Frontiers in Immunology;2024-05-23

4. Biological therapy optimization in patients with psoriasis by reducing the dose or increasing the time interval, in a specialized centre in Colombia;Revista Colombiana de Reumatología (English Edition);2023-07

5. Biological therapy optimization in patients with psoriasis by reducing the dose or increasing the time interval, in a specialized centre in Colombia;Revista Colombiana de Reumatología;2023-07